Onkológia 5/2021

Treatment options for PRRT in patients with neuroendocrine neoplasia

Peptide radionuclide receptor therapy has been part of the treatment algorithm in patients with inoperable and / or metastatic NEN for more than 15 years. The development of new radiopharmaceuticals and the use of more efficient radionuclides have enabled its more widespread use. Together with a more accurate diagnostic of somatostatin receptor expression, PRRT is part of theranostics - a concept that combines specific targeted diagnosis and specific targeted treatment. The possibilities of using PRRT have their specifics - indication and contraindication criteria, regime measures and method of administration. With the good cooperation of a multidisciplinary team, the right procedures to ensure the necessary quality of the therapeutic radiopharmaceutical and the right principles of radiation protection of patients, staff and family members, this type of treatment is very effective and safe. It has been available in Slovakia since 2020, so patients do not have to travel abroad for this treatment. In our review article, we tried to approach the origin of PRRT, its modern form as part of theranostics, as well as practical aspects of its use.

Keywords: PRRT, peptide receptor radionuclide therapy, NEN, neuroendocrine tumors, lutetium, 177Lu-DOTATATE, 68Ga-DOTATOC, DOTA peptides, somatostatin receptors, theranostics